Neal Futran

Neal Futran

Auto-generated profile, based on publicly available information

Neal Futran

Department of Otolaryngology-Head and Neck Surgery, University of Washington School of Medicine, Seattle, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in Otolaryngologic Clinics of North America
Verified
Journal Article
Closed access
SSSeth R Schwartz
Seth R Schwartz
NFNeal D Futran
Neal D Futran

30 June 2020 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
HCHarrison Cash
Harrison Cash
RHR. Alex Harbison
R. Alex Harbison
NFNeal Futran
Neal Futran
UPUpendra Parvathaneni
Upendra Parvathaneni
GLGeorge E. Laramore
George E. Laramore
JHJeffrey J. Houlton
Jeffrey J. Houlton

1 August 2018 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
NFNeal Futran
Neal Futran
The goals of head and neck reconstruction of cancer-related defects are to restore speech, swallowing, and cosmesis and maximize patient quality of life. During the past 2 decades, our ability to achieve these goals with free, pedicled, and local tissue transfer alone or in combination has steadily improved. The reconstructive surgeon now has a robust armamentarium with an array of tissue choices, including bone, muscle, viscera, skin (thick, thin, hair bearing, and color match to facial skin). In addition, there has been an expansion of recipient vessels, which allows an increased range of options for patients in whom prior therapy has failed and who present for head and neck reconstruction. These advances have changed the way that we think about the various components of the head and neck and increased the number of creative choices to restore form and function and minimize morbidity.

1 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NUNatalie F. Uy
Natalie F. Uy
KNKevin Ng
Kevin Ng
JVJenna M. Voutsinas
Jenna M. Voutsinas
VWVicky Wu
Vicky Wu
NFNeal D. Futran
Neal D. Futran
CRCristina P. Rodriguez
Cristina P. Rodriguez
296 Background: Immune checkpoint inhibitors (ICI) are approved for recurrent and/or metastatic squamous head and neck cancers (R/M HNSCC). Landmark trials have shown stable or improved patient (pt) reported quality of life outcomes. It is unclear how these translate into gastrostomy (G) and tracheostomy (T) dependence, opioid use, or ER/unplanned hospitalizations (UH) in an unselected population. We sought to explore these in our large single institution cohort. Methods: We reviewed R/M HNSCC pts receiving ICI at a tertiary referral NCI designated cancer center. Outcomes were assessed between the first dose of ICI and 100 days after the last dose of ICI. Overall survival (OS) was estimated via Kaplan-Meier estimation. Differences between groups were assessed via log-rank testing procedure and adjusted for age, tumor characteristics, and smoking status. Results: Between 1/2012 and 12/2019, we treated 152 pts with ICI, mostly male (n = 142, 82%), partnered/married (n = 103, 68%), with median age 64 years (range 23 – 90). The most common primary sites were oropharynx (n = 55, 36%) and oral cavity (n = 33, 22%). 50 (35%) had ≥2 lines of prior systemic therapy and 29 (19%) had an ECOG ≥2. The most common pt races were white (n = 114, 75%), Asian (n = 14, 9%), and Hispanic, any race (n = 6, 4%). 83 (55%) and 23 (15%) had history of smoking and heavy alcohol use respectively. Median duration of ICI therapy was 95 days (range 1-1720). Prior to ICI, 49 (32%) had G, 17 (11%) had T, and 15 (10%) had both. While on ICI, 6 (4%) had G placed, and 1 (1%) had a G removed; 1 (1%) had T placed, and 2 (1%) had T removed. 69 (45%) had ER visits and 57 (38%) had UH; 11 (7%) were directly related to ICI adverse effects. Prior to ICI, 104 (68%) were on opiates; requirements increased in 58 (41%) pts and decreased in 17 (12%) pts. Pre-existing G prior to ICI had worse OS on log-rank testing, but significance was lost when adjusted for variables. Pre-existing T prior to ICI (p = 0.001, HR 3.08, 95% Cl [1.56,6.08]), and pts with increasing opiate requirements on ICI (p value = 0.0007, HR 2.13, 95% Cl [1.38,3.28]) had worse OS. Conclusions: In our cohort, ICI did not change G or T usage. Pre-existing T and increasing opiate use were also associated with worse survival. Our data supports augmentation of palliative care and advanced care planning in the R/M HNSCC population.

19 February 2026 in Oral Oncology
Verified
Journal Article
Closed access
MUMateo Useche
Mateo Useche
ANArmita Norouzi
Armita Norouzi
JLJay Justin Liao
Jay Justin Liao
NPNeil Panjwani
Neil Panjwani
GLGeorge E. Laramore
George E. Laramore
BBBrittany Barber
Brittany Barber